Hims & Hers Health Stock Jumps Again as Novo Nordisk Deal Ends Wegovy Fight
Hims & Hers Health shares rose 11% Tuesday after Novo Nordisk agreed to sell Wegovy and Ozempic through its platform, ending a recent patent dispute. Hims will offer the drugs at Novo’s self-pay prices and limit compounded GLP-1 products to select cases. Novo will withdraw its lawsuit but may refile. The agreement follows a 40% jump in Hims’ stock Monday.